Bausch + Lomb Progresses Oral AMD Treatment Development After FDA Discussion

Bausch + Lomb has advanced its investigational oral treatment, BL1243 (tonabersat), for early-stage dry age-related macular degeneration. A recent meeting with the FDA clarified the clinical development pathway, with a new program expected to commence in 2027. This development is significant as current treatment options for earlier-stage dry AMD are limited, potentially offering a new therapeutic approach for patients.